GEMoaB monoclonals

from Wikipedia, the free encyclopedia
GEMoaB Monoclonals GmbH
legal form Company with limited liability
founding 2011
Seat Dresden , GermanyGermanyGermany 
management Michael Pehl, Chief Executive Officer (CEO),
Gerhard Ehninger , Chief Medical Officer (CMO)
Number of employees n / A
sales n / A
Branch Pharmaceutical manufacturer
Website www.gemoab.com
As of April 30, 2020

GEMoaB Monoclonals GmbH is a German biopharmaceutical company that deals with the development of innovative cancer therapies. The company's focus is on next-generation CAR T-cell therapies . The company was founded in 2011 by the two professors Gerhard Ehninger and Michael Bachmann .

Corporate background

The company focuses on cell therapies, so-called CAR-T therapies. The body's own T cells are genetically modified to fight cancer cells so that they are able to better recognize and kill tumors. GEMoaB's platform technologies (UniCAR, RevCAR and ATAC) have the potential to address malignant hematological as well as solid tumor diseases.

What is interesting about the GEMoaB approach is that the CAR-T cells can be switched on and off quickly in the patient's body using an adapter molecule, the so-called targeting module, so that side effects of the therapy can be better controlled and thus patient safety is increased can be.

The company's headquarters are in Dresden .

Scientific and strategic advisory board

The company's scientific advisory board consists of: Gerhard Ehninger (Chairman), Michael Bachmann (Dresden), Katy Rezvani (USA), Bob Löwenberg (Netherlands) and Thomas de Maizière , Member of the Bundestag.

Cooperations

GEMoaB Monoclonals cooperates with a number of partners: the sister company Cellex in Cologne, the Fraunhofer Institute , the pharmaceutical company Bristol-Myers Squibb as well as the companies ABX, Bio Elpida and the Saxon Ministry of Research.

Projects in the pipeline

  • GEM333: Affinity-Tailored Adapters for T-Cells (ATAC) against CD33 in AML
  • GEM3PSCA, ATAC against PSCA in prostate cancer and other PSCA-expressing solid tumors
  • UniCAR-T-CD123 for the treatment of AML, ALL and certain lymphomas
  • UniCAR-T-PSMA, used to treat a variety of PSMA- expressing tumors

literature

  • Nicola Mitwasi et al .: “UniCAR” -modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumor cells In: Nature Scientific Reports , Volume 10, 2020, p. 2141. doi : 10.1038 / s41598-020 -59082-4 , PMID 32034289 .
  • Loff, S., Meyer, J.-E., Dietrich, J., Spehr, J., Julia, R., von Bonin, M., Founder, C., Franke, K., Feldmann, A., Bachmann , M., Ehninger, G., Ehninger, A., Cartellieri, M .: Late-Stage Preclinical Characterization of Switchable CD123-Specific CAR-T for Treatment of Acute Leukemia In: Blood , 132, 2018, pp. 964-964 . doi : 10.1182 / blood-2018-99-113288 .
  • Arndt, C., Feldmann, A., Koristka, S., Schafer, M., Bergmann, R., Mitwasi, N., Berndt, N., Bachmann, D., Kegler, A., Schmitz, M., Puentes-Cala, E., Soto, JA, Ehninger, G., Pietzsch, J., Liolios, C., Wunderlich, G., Kotzerke, J., Kopka, K., Bachmann, M .: A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR In: Oncoimmunology , Volume 8, 2019, Article: 1659095. doi : 10.1080 / 2162402X.2019.1659095 , PMID 31646084 .
  • C. Arndt, M. von Bonin et al .: Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. In: Leukemia , Volume 27, Number 4, April 2013, pp. 964-967, doi : 10.1038 / leu.2013.18 , PMID 23325142 .

See also

Web links

Individual evidence

  1. ↑ Management Team , Company Website, accessed May 7, 2020
  2. ↑ GEMoaB - Next Generation Immunotherapies , Company Website, accessed April 29, 2020
  3. ↑ M. Cartellieri, A. Feldmann et al: Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. In: Blood Cancer Journal . Volume 6, number 8, 08 2016, p. E458, doi : 10.1038 / bcj.2016.61 , PMID 27518241 , PMC 5022178 (free full text).
  4. ^ Scientific and Strategic Advisory Board , Company Website, accessed April 29, 2020
  5. ^ Our Partners , Company Website, accessed April 29, 2020
  6. ↑ AML: GEM333-01 , National Center for Tumor Diseases Dresden, accessed on April 29, 2020
  7. ↑ Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia , clinicaltrials.gov, accessed April 29, 2020
  8. ↑ Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker , clinicaltrials.gov, accessed April 29, 2020